Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track BOLD with free AI briefings, catalyst countdowns, and dilution alerts.

BOLD · Boundless Bio, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$62.9M Cash on Hand
11.8mo Cash Runway
Follow BOLD by email Get an email when BOLD reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about BOLD, unsubscribe in one click. Privacy

📣 What BOLD Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Chk1 Inhibitor BBI-355 Triple Negative Breast Cancer (TNBC) Phase 1 · NCT05827614 Terminated
RNR Inhibitor BBI-825 Triple Negative Breast Cancer (TNBC) Phase 1 · NCT05827614 Terminated
Kinesin Degrader BBI-940 Breast Cancer Phase 1 · NCT07408089 Terminated

Also used in these trials (approved or third-party drugs, not BOLD's own candidates): Erlotinib Hydrochloride, Fulvestrant, Futibatinib.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

BOLD holds $62.9M in cash and short-term investments (as of Sep 30, 2026) and burns about $15.9M/quarter from operations, an estimated runway of 11.8 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 55 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when BOLD files for a raise →

👥 Who Owns BOLD

Insiders 17.9% Other 5%+ holders 22.3% Institutions (44 holders) 59.8% Public and other holders 0%
HolderTypeShares% of sharesAs of
Kevin Tang
10% owner
Insider 3,035,567 12.86% 2026-11-06
TANG CAPITAL MANAGEMENT, LLC 5%+ holder (13G) 2,840,635 12.03% 2026-09-30
FMR LLC Institution (13G, 5%+) 2,684,022 11.37% 2025-12-31
Zachary Hornby 5%+ holder (13G) 2,426,857 10.28% 2025-10-14
ADAR1 Capital Management, LLC Institution (13G, 5%+) 1,968,216 8.34% 2026-06-30
Kenneth Griffin Institution (13G, 5%+) 1,433,388 6.07% 2025-11-26
ARCH Venture Fund IX, L.P.
10% owner
Insider 1,181,766 5.01% 2026-07-01
Keith Crandell
10% owner
Includes shares also reported by ARCH Venture Fund IX, L.P., counted once
Insider 1,181,766 5.01% 2026-07-01
Kristina Burow
Director, 10% owner · +16,000 options
Includes shares also reported by ARCH Venture Fund IX, L.P., counted once
Insider 1,181,766 5.01% 2024-04-02
David A Hinkle
Senior VP, Finance, Controller and Treas · +205,000 options
Insider 100 0.00% 2024-10-11

Share count 23,611,406 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full BOLD picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BOLD and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.